Intervention Review

You have free access to this content

Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis

  1. Loredana La Mantia1,2,
  2. Carlo Di Pietrantonj3,
  3. Marco Rovaris1,
  4. Giulio Rigon4,
  5. Serena Frau5,
  6. Francesco Berardo6,
  7. Anna Gandini7,
  8. Anna Longobardi4,
  9. Bianca Weinstock-Guttman8,
  10. Alberto Vaona4,*

Editorial Group: Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group

Published Online: 26 JUL 2014

Assessed as up-to-date: 2 NOV 2013

DOI: 10.1002/14651858.CD009333.pub2


How to Cite

La Mantia L, Di Pietrantonj C, Rovaris M, Rigon G, Frau S, Berardo F, Gandini A, Longobardi A, Weinstock-Guttman B, Vaona A. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. Cochrane Database of Systematic Reviews 2014, Issue 7. Art. No.: CD009333. DOI: 10.1002/14651858.CD009333.pub2.

Author Information

  1. 1

    I.R.C.C.S. Santa Maria Nascente - Fondazione Don Gnocchi, Unit of Neurorehabilitation - Multiple Sclerosis Center, Milano, Italy

  2. 2

    AO Ospedale Niguarda Ca' Granda, Department of Neurosciences - Multiple Sclerosis Centre, Milano, Italy

  3. 3

    Local Health Unit Alessandria- ASL AL, Regional Epidemiology Unit SeREMI- Cochrane Vaccines Field, Alessandria, Alessandria, Italy

  4. 4

    Azienda ULSS 20 - Verona, Primary Care, Verona, Italy

  5. 5

    Dialogo sui Farmaci S.r.l., Verona, Italy

  6. 6

    Azienda Ospedaliera di Verona - Department of Pharmacy, Drug Efficacy Evaluation Unit (UVEF) - Veneto Regional Drug Information Center, Verona, Italy

  7. 7

    Azienda ULSS 21 - Legnago, Regional Health Service, Legnago, Varese, Italy

  8. 8

    SUNY University of Buffalo, Director, Jacobs MS Center and Pediatric MS Center of Excellence, Buffalo, New York, USA

*Alberto Vaona, Primary Care, Azienda ULSS 20 - Verona, Via Regaste San Zeno, 37, Verona, 37123, Italy. aisamaisa@gmail.com.

Publication History

  1. Publication Status: New
  2. Published Online: 26 JUL 2014

SEARCH

References

References to studies included in this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. References to ongoing studies
  5. Additional references
Cadavid 2009 {published data only}
  • Cadavid D, Cheriyan J, SkurnickJ, LincolnJ A, Wolansky LJ, Cook SD. New acute and chronic black holes in patients with multiple sclerosis randomised to interferon beta-1b or glatiramer acetate. Journal Neurology Neurosurgery and Psychiatry 2009;80:1337-43.
  • Cadavid D, Kim S, Peng B, Skurnick J, Younes M, Hill J, et al. Clinical consequences of MRI activity in treated multiple sclerosis. Multiple Sclerosis Journal 2011;17(9):1113–21.
  • Cadavid D, Wolansky LJ, Skurnick J, Lincoln J, Cheriyan J, Szczepanowski K, et al. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology 2009;72(23):1976-83.
  • Cheriyan J, Kim S, Wolansky LJ, Cook SD, Cadavid D. Impact of inflammation on brain volume in multiple sclerosis. Archives of Neurology 2012;69:82-8.
  • NCT00176592. Phase IV, rater-blinded, randomized study comparing 250 mg of Betaseron with 20 mg of Copaxone in patients with the relapsing-remitting (RR) or CIS forms of ms using 3 Tesla (3T) magnetic resonance imaging (MRI) with triple-dose gadolinium. http://clinicaltrials.gov/ct2/show/NCT00176592 (accessed 25 October 2013).
Calabrese 2012 {published data only}
  • Calabrese M, Bernardi V, Atzori M, Mattisi I, Favaretto A, Rinaldi F, et al. Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing–remitting multiple sclerosis. Multiple Sclerosis Journal 2012;18(4):418–24.
Lublin 2013 {published data only}
  • Lindsey JW, Scott TF, Lynch SG, Cofield SS, Nelson F, Conwit R, et al. The CombiRx trial of combined therapy with interferon and glatiramer acetate in relapsing remitting MS: design and baseline characteristics. Multiple Sclerosis and Related Disorders 2012;1:81-6.
  • Lublin F, Cofield S, Cutter G, Conwit R, Narayana P, Nelson F, et al. The CombiRx trial: a multi-center, double-blind, randomized study comparing the combined use of interferon beta-1a and glatiramer acetate to either agent alone in participants with relapsing remitting multiple sclerosis - clinical outcomes. Proceedings of Neurology vol 78, abstracts 1, PL02.003, April 27. 2012. [: 64th American Academy of Neurology Annual Meeting, New Orleans]
  • Lublin F, Cofield S, Cutter G, Salter A, Wang J, Conwit R, et al. EDSS changes in CombiRx: blinded, 7-year extension results for progression and improvement. Proceedings of Neurology vol 80, P04.121, abstract 1, February 12. 2013. [: The American Academy of Neurology's 65th AAN Annual Meeting, San Diego]
  • Lublin FD, Cofield SS, Cutter GR, Conwit R, Narayana PA, Nelson F, et al. Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Annals of Neurology 2013;73:327–40.
  • Wolinsky J, Narayana P, Nelson F, Datta S, Cofield S, Cutter G, et al. The CombiRx trial: a multi-center, double-blind, randomized study comparing the combined use of interferon beta-1a and glatiramer acetate to either agent alone in participants with relapsing remitting multiple sclerosis - MRI outcomes. Proceedings of Neurology vol 78, abstracts S11.002, April 24. 2012. [: 64th American Academy of Neurology Annual Meeting, New Orleans]
  • Wolinsky J, Salter A, Narayana P, Datta S, Nelson F, Cofield S, et al. MRI outcomes in CombiRx: blinded, 7-year extension results. Proceedings of Neurology vol 80, abstract 1, S01.003, February 12. 2013. [: The American Academy of Neurology's 65th AAN Annual Meeting, San Diego]
Mikol 2008 {published data only}
  • Coyle PK, Cornelisse P, Lehr L, Stubinski B. Time course of injection-site reactions to subcutaneous interferon beta-1a or glatiramer acetate in the REGARD Study. Proceedings of the 24th Annual Meeting of the Consortium of Multiple Sclerosis Centers, June 2–5, San Antonio, Texas, USA. 2010.
  • Mikol DD, Barkhof F, Chang P, Coyle PK, Jeffery DR, Schwid SR, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurology 2008;7(10):903-14.
  • Sørensen S. REGARD: what can we learn from randomised, open-label, head-to-head studies?. The Lancet 2008;7:864-6.
O'Connor 2009 {published data only}
  • Filippi M, Rocca MA, Camesasca F, Cook S, O’Connor P, Arnason BG, et al. Interferon-1b and glatiramer acetate effects on permanent black hole evolution. Neurology 2011;76:1222–8.
  • Goodin DS, Hartung HP, O'Connor P, Filippi M, Arnason B, Comi G, et al. Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the beyond trial. Multiple Sclerosis 2012;18:181-95.
  • Lampl C, Nagl S, Arnason B, Comi G, O Connor P, Cook S, et al. Efficacy and safety of interferon beta-1b SC in older RRMS patients-a post hoc analysis of the BEYOND study. Journal of Neurology 2013;260(7):1838-45.
  • O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, et al. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurology 2009;8(10):889-97.
  • O’Connor P, Arnason B, Comi GC, Filippi M, Cook S, Newark NJ, et al. Interferon beta-1b 500 mcg, Interferon beta-1b 250 mcg and glatiramer acetate: primary outcomes of the betaferon® efficacy yielding outcomes of a new dose study. Proceeding of the 60th American Academy of Neurology Annual Meeting 153 vol 71 LBS.004. 2008.
  • O’Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D. 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study [Errata]. Lancet Neurology 2011; Vol. 10, issue 2:115.
  • O’Connor P, Filippi M, Arnason B, et al. 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study [Errata]. Lancet Neurology 2009;8(11):981.
  • O’Connor P, Filippi M, Arnason B, et al. for the BEYOND Study Group. 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study [Errata]. Lancet Neurology 2012;11(1):27.
  • Pleimes D, Pohl C, Beckmann K, Stolz C. BEYOND Study – Data for Cochrane Analyses Protocol No. 306440. Bayer HealthCare Pharmaceuticals Affairs Specialized Therapeutics 2013.

References to studies excluded from this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. References to ongoing studies
  5. Additional references
Barbato 2011 {published data only}
  • Barbato LM, Schofield L, McCague K, Pestreich L, Tobias K, Malhotra M, et al. Randomized, open-label study to evaluate patient-reported outcomes (PRO) with fingolimod after changing from prior disease-modifying therapy (DMT) for relapsing multiple sclerosis. Proceedings of the 136th Annual Meeting Sunday, T1735. S73, September 25. 2011.
Beer 2011 {published data only}
  • Beer K, Müller M, Hew-Winzeler AM, Bont A, Maire P, You X, et al. The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: an observational study. Bacteriologia, Virusologia, Parazitologia, Epidemiologia 2011;11(144):2-7.
Carra 2008 {published data only}
Carter 2010 {published data only}
  • Carter NJ, Keating GM. Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis. Drugs 2010;70(12):1545-77.
Comi 2009 {published data only}
  • Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009;374:1503–11.
Comi 2011 {published data only}
Del Santo 2011 {published data only}
  • Del Santo F, Maratea D, Fadda V, Trippoli S, Messori A. Treatments for relapsing–remitting multiple sclerosis: summarising current information by network meta-analysis. European of Journal Clinical Pharmacology 2011;68(4):441-8.
Ghezzi 2005 {published data only}
  • Ghezzi A, Amato MP, Capobianco M, Gallo P, Marrosu G, Martinelli V, et al. Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study. Multiple Sclerosis 2005;11(4):420-4.
Khan 2001 {published data only}
  • Khan OA, Tselis AC, Kamholz JA, Garbern JY, Lewis RA, Lisak RP. A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis: results after 18 months of therapy. Multiple Sclerosis 2001;7(6):349-53.
Khan 2012 {published data only}
  • Khan O, Bao F, Shah M, Caon C, Alexandros T, Selis A, et al. Effect of disease-modifying therapies on brain volume in relapsing–remitting multiple sclerosis: results of a five-year brain MRI study. Journal of the Neurological Sciences 2012;312:7–12.
Khan 2013 {published data only}
Khoury 2010 {published data only}
  • Khoury SJ, Healy BC, Kivisäkk P, Viglietta V, Egorova S, Guttmann CR, et al. A randomized controlled double-masked trial of albuterol add-on therapy in patients with multiple sclerosis. Archives of Neurology 2010;67(9):1055-61.
NCT01058005 {unpublished data only}
  • NCT01058005. Phase IIIa multicenter, randomized, open-label, parallel-group, active-controlled study to evaluate the benefits of switching therapy (glatiramer acetate or interferon beta-1a) to natalizumab in subjects with relapsing remitting multiple sclerosis. Study evaluating rebif, copaxone, and tysabri for active multiple sclerosis (SURPASS). http://clinicaltrials.gov/show/NCT01058005 (accessed 17 December 2013).
Ouallet 2010 {published data only}
  • Ouallet JC. Immunomodulatory treatments for multiple sclerosis: lessons from direct comparative studies [Traitements de fond de la sclérose en plaques: enseignements des études randomisées comparatives directes]. Reveu Neurologique 2010;166(1):21-31.
Qizilbash 2012 {published data only}
  • Qizilbash N, Mendez I, Sanchez-de la Rosa R. Benefit-risk analysis of glatiramer acetate for relapsing-remitting and clinically isolated syndrome. Multiple Sclerosis Clinical Therapy 2012;34:159-76.

References to studies awaiting assessment

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. References to ongoing studies
  5. Additional references
Salama 2003 {published data only}
  • Salama HH, Abu-Hashim EM, El Bakry MA, Zhang J, El Mongui A. Twelve-month comparative study of the impacts of IFNb-1a (Avonex), IFNb-1b (Betaseron) and glatiramer acetate (Copaxone) on the clinical, MRI and immunological responses in relapsing-remitting multiple sclerosis. Neurosciences (Official Journal of the Pan Arab Union of Neurological Sciences) 2003;8:93-4.

References to ongoing studies

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. References to ongoing studies
  5. Additional references
NCT00176592 {published data only}
  • NCT00176592. Phase IV, rater-blinded, randomized study, comparing 250 mg of betaseron with 20 mg of copaxone in patients with the relapsing-remitting(RR) or CIS forms of ms using 3 tesla (3T) magnetic resonance imaging (MRI) with triple-dose gadolinium. ClinicalTrials.gov/show/NCT00176592 (accessed 25 October 2013).

Additional references

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. References to ongoing studies
  5. Additional references
Alonso 2008
Cadavid 2009a
  • Cadavid D, Cheriyan J, Skurnick J, Lincoln JA, Wolansky LJ, Cook SD. New acute and chronic black holes in patients with multiple sclerosis randomised to interferon beta-1b or glatiramer acetate. Journal Neurology Neurosurgery and Psychiatry 2009;80:1337-43.
Cadavid 2011
  • Cadavid D, Kim S, Peng B, Skurnick J, Younes M, Hill J, et al. Clinical consequences of MRI activity in treated multiple sclerosis. Multiple Sclerosis Journal 2011;17(9):1113–21.
Chard 2011
  • Chard DT, Dalton CM, Swanton J, Fisniku LK, Miszkiel KA, Thompson AJ, et al. MRI only conversion to multiple sclerosis following a clinically isolated syndrome. Journal of Neurology Neurosurgery and Psychiatry 2011; Vol. 82, issue 2:176-9.
Cheriyan 2012
Comi 2001
  • Comi G, Filippi M, Wolinsky JS, European/Canadian Glatiramer Acetate Study Group. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging—measured disease activity and burden in patients with relapsing multiple sclerosis. Annals of Neurology 2001;49:290–7.
Compston 2008
Coyle 2010
  • Coyle PK, Cornelisse P, Lehr L, Stubinski B. Time course of injection-site reactions to subcutaneous interferon beta-1a or glatiramer acetate in the REGARD Study. Proceedings of 24th Annual Meeting of the Consortium of Multiple Sclerosis Centers, June 2–5, San Antonio, Texas, USA. 2010.
DerSimonian 1986
Dhib-Jalbut 2010
FDA 1993
  • U.S. Food, Drug Administration. BETASERON Product Approval Information - Application No 103471- July 1993. http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/103471s0000_APPROV.pdf (accessed January 2011).
FDA 1996
  • U.S. Food, Drug Administration. AVONEX Product Approval Information - Application N. 103628 - May 1996. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/1996/ifnbbio051796l.pdf (accessed January 2011).
FDA 2001
  • U.S. Food, Drug Administration. Copaxone Product Approval Information - NDA 020622/S-015 - March 2001. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020622_S015_COPAXONE_INJECTION_AP.pdf (accessed January 2011).
FDA 2002
  • FDA. REBIF Product Approval Information - Application No 103780 - March 2002. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm094508.pdf (accessed January 2011).
FDA 2009
  • FDA. EXTAVIA Product Approval Information - Application No.125290 - August 2009. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/125290s0000ltr.pdf (accessed January 2011).
FDA 2013
  • U.S. Food, Drug Administration. Safety - What is a Serious Adverse Event?. http://www.fda.gov/safety/medwatch/howtoreport/ucm053087.htm (accessed November 2013).
Filippi 2011
Filippini 2013
Fisniku 2008
Goodin 2008
  • Goodin DS. Disease-modifying therapy in multiple sclerosis. Update and clinical implications. Neurology 2008;71 Suppl 3:8–13.
Goodin 2008a
  • Goodin D. Comparative studies of glatiramer acetate and interferon beta. International Multiple Sclerosis Journal 2008;15(2):39-41.
Goodin 2012
  • Goodin DS, Hartung HP, O'Connor P, Filippi M, Arnason B, Comi G, et al. Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial. Multiple Sclerosis 2012;18:181-95.
GRADE Working Group 2004
  • GRADE Working Group. Grading quality of evidence and strength of recommendations. British Medical Journal 2004;328:1490-4.
GRADEpro 2008
  • Brozek J, Oxman A, Schunemann H. GRADEpro. 3.2 for Windows. GRADE Working Group, 2008.
Hadjigeorgiou 2013
Higgins 2003
Higgins 2011
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
Hillert 2012
  • Hillert J. In the coming year we should abandon interferons and glatiramer acetate as first line therapy for MS: No. Multiple Sclerosis Journal 2012;19(1):26-8.
Hutchinson 2012
  • Hutchinson M. In the coming year we should abandon interferons and glatiramer acetate as first line therapy for MS: commentary. Multiple Sclerosis Journal 2012;19(1):29-30.
IFN MSSG 1995
  • The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655–61.
Jacobs 1996
  • Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Annals of Neurology 1996;39(3):285–94.
Johnson 1995
  • Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multi-center, double-blind placebo-controlled trial: the Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995;45(7):1268–76.
Kurtzke 1983
La Mantia 2010
  • La Mantia, Munari LM, Lovati R. Glatiramer acetate for multiple sclerosis. Cochrane Database of Systematic Reviews 2010, Issue 5. [DOI: 10.1002/14651858.CD004678.pub2]
Lampi 2013
  • Lampl C, Nagl S, Arnason B, Comi G, O Connor P, Cook S, et al. Efficacy and safety of interferon beta-1b sc in older RRMS patients-a posthoc analysis of the BEYOND study. Journal of Neurology 2013;260(7):1838-45.
Lindsey 2012
  • Lindsey JW, Scott TF, Lynch SG, Cofield SS, Nelson F, Conwit R, et al. The CombiRx trial of combined therapy with interferon and glatiramer acetate in relapsing remitting MS: design and baseline characteristics. Multiple Sclerosis and Related Disorders 2012;1:81-6.
Lublin 2012
  • Lublin F, Cofield S, Cutter G, Conwit R, Narayana P, Nelson F, et al. The CombiRx trial: a multi-center, double-blind, randomized study comparing the combined use of interferon beta-1a and glatiramer acetate to either agent alone in participants with relapsing remitting multiple sclerosis - clinical outcomes. Proceedings of the 64th American Academy of Neurology Annual Meeting, PL02.00, Neurology Volume 78, April 24. 2012.
Lublin 2013a
  • Lublin F, Cofield S, Cutter G, Salter A, Wang J, Conwit R, et al. EDSS changes in CombiRx: blinded, 7-year extension results for progression and improvement. Proceedings of the 65th American Academy of Neurology (AAN) Annual Meeting, Neurology vol 80. 2013.
Lublin 2013b
  • Lublin F, Cofield S, Cutter G, Salter A, Wang J, Conwit R, et al. Relapse activity in the CombiRx trial: blinded, 7-year extension results. Proceedings of the 65th American Academy of Neurology (AAN) Annual Meeting, Neurology vol 80. 2013.
McDonald 2001
O'Connor 2008
  • O’Connor P, Arnason B, Comi G, Filippi M, Cook S, Goodin D, et al. Interferon beta-1b 500 mcg, interferon beta-1b 250 mcg and glatiramer acetate: primary outcomes of the Betaferon® efficacy yielding outcomes of a new dose study. Neurology 2008;71:153.
O'Connor 2009a
  • O’Connor P, Filippi M, Arnason B, Comi G, Cook S, Gooding D, et al. 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Errata. Lancet Neurology 2009;8:981.
O'Connor 2011
  • O’Connor P, Filippi M, Arnason B, Comi G, Cook S, Gooding D, et al. 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Errata. Lancet Neurology 2011; Vol. 10:115.
O'Connor 2012
  • O’Connor P, Filippi M, Arnason B, Comi G, Cook S, Gooding D, et al. 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Errata. Lancet Neurology 2012;11:27.
Oleen-Burkey 2013
  • Oleen-Burkey M, Cyhaniuk A, Swallow E. Treatment patterns in multiple sclerosis: administrative claims analysis over 10 years. Journal of Medical Economics 2013;16(3):397-406.
Oliver 2010
  • Oliver BJ, Kohli E, Kasper LH. Interferon therapy in relapsing-remitting multiple sclerosis: a systematic review and meta-analysis of the comparative trials. Journal of the Neurological Sciences 2010 Dec 15 [Epub ahead of print].
Parkenov 2013
Pleimes 2013
  • Pleimes D, Pohl C, Beckmann K, Stolz C. BEYOND Study – Data for Cochrane Analyses Protocol No. 306440. Bayer HealthCare Pharmaceuticals Affairs Specialized Therapeutics 2013.
Polman 2005
Polman 2011
Popescu 2013
  • Popescu V, Agosta F, Hulst HE, Sluimer IC, Knol DL, Sormani MP, et al. Brain atrophy and lesion load predict long term disability in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry 2013;84(10):1082-91.
Poser 1983
PRISMS 1998
  • PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498–504.
Racke 2010
Review Manager 2013
  • The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2013.
Rice 2001
  • Rice GPA, Incorvaia B, Munari LM, Ebers G, Polman C, D’Amico R, et al. Interferon in relapsing-remitting multiple sclerosis. Cochrane Database of Systematic Reviews 2001, Issue 4. [DOI: 10.1002/14651858.CD002002]
Richards 2002
  • Richards R, Sampson F, Beard S, Tappenden P. A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models. Health Technology Assessment 2002;6(18):1-73. [MEDLINE: 12022938]
Rotstein 2010
Rudick 2009
Rudick 2010
  • Rudick RA, Lee LC, Cutter GR, Miller DM, Bourdette D, Weinstock-Guttman B, et al. Disability progression in a clinical trial of relapsing-remitting multiple sclerosis: eight year follow-up. Archives of Neurology 2010 12 Jul [Epub ahead of print].
Schünemann 2011
  • Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and ‘Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
Sorensen 2008
  • Sørensen S. REGARD: what can we learn from randomised, open-label, head-to-head studies?. The Lancet 2008; Vol. 7:864-6.
Sterne 2011
  • Sterne JAC, Egger M, Moher D (editors). Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
Vickrey 1995
Weinshenker 1989
  • Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989;112:133-46.
Weinstock Guttman 2008
Wolinski 2012
  • Wolinsky J, Narayana P, Nelson F, Datta S, Cofield S, Cutter G, et al. The CombiRx trial: a multi-center, double-blind, randomized study comparing the combined use of interferon beta-1a and glatiramer acetate to either agent alone in participants with relapsing remitting multiple sclerosis - MRI outcomes. Proceedings of the 64th American Academy of Neurology Annual Meeting, abstract S11.002, Neurology Vol 78 April 24. 2012.
Wolinsky 2013
  • Wolinsky J, Salter A, Narayana P, Datta S, Nelson F, Cofield S, et al. MRI outcomes in CombiRx: blinded, 7-year extension results. Proceedings of the 65th American Academy of Neurology (AAN) Annual Meeting, Neurology vol 80. 2013.
Yusuf 1985
Zagmutt 2013
  • Zagmutt F, Carroll C. A network meta-analysis assessing the rate of adverse events and drop outs of alternative treatments for relapsing forms of multiple sclerosis. Proceedings of the 65th American Academy of Neurology (AAN) Annual Meeting, Neurology vol 80. 2013.
Zivadinov 2008
  • Zivadinov R, Reder AT, Filippi M, Minagar A, Stüve O, Lassmann H, et al. Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis . Neurology 2008;71(2):136-44.